GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have...
Myeloma NZ
MRP a valuable risk assessment tool for newly diagnosed multiple myeloma
A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.
Dr. Hari on the Role of MRD in Multiple Myeloma
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin…
Study Identifies Independent Predictors of Smoldering Multiple Myeloma Progression
A series of molecular abnormalities in smoldering multiple myeloma that are independent predictors of progression to multiple myeloma were...
Article of the week: Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd)...
Multiple Myeloma Research Review
Highlights include: Associations with OS in NZ MM patients VTE risk with lenalidomide regimens for MM despite thromboprophylaxis Retrospective study...
Australian clinicians report on real world use of bortezomib in elderly MM patients
Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more...
Article of the week: Once-versus twice-weekly car fi lzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most common...
Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or...
Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively...
COVID-19’s Impact on How Patients with CLL, Myeloma Have Received Treatment
CURE® recently invited patients, survivors, caregivers, advocates and health care professionals to attend its first-ever live webinar, “Hear from...
Newsletter: Autumn 2020
Hello Everybody I hope that you are all coping with the lock-down as best that you can. It’s been a difficult time for many people and especially...